INSIDER
01Overview02Daily Brief03Live04Congress05Corporate Insiders06Government Money07Political Influence08Institutions09Washington Network10Follow the Power11Disclosure Clock12AI Investigator13Watchlist
ConvergenceINSIDER AlphaSignal ledgerHistorical ReplayRobinhood ChainProofTradingTokenProMethodologyMatch reviewLaunch readiness
Data sources

Public disclosures only. Scores flag unusual patterns and are not evidence of wrongdoing. Not investment advice.

RH CHAIN…
OverviewDaily BriefLiveCongressCorporate InsidersGovernment MoneyPolitical InfluenceInstitutionsWashington NetworkFollow the PowerDisclosure ClockAI InvestigatorWatchlistConvergenceINSIDER AlphaSignal ledgerHistorical ReplayRobinhood ChainProofTradingTokenProMethodologyMatch reviewLaunch readiness
01Overview02Daily Brief03Live04Congress05Corporate Insiders06Government Money07Political Influence08Institutions09Washington Network10Follow the Power11Disclosure Clock12AI Investigator13Watchlist
ConvergenceINSIDER AlphaSignal ledgerHistorical ReplayRobinhood ChainProofTradingTokenProMethodologyMatch reviewLaunch readiness
OverviewDaily BriefLiveCongressCorporate InsidersGovernment MoneyPolitical InfluenceInstitutionsWashington NetworkFollow the PowerDisclosure ClockAI InvestigatorWatchlistConvergenceINSIDER AlphaSignal ledgerHistorical ReplayRobinhood ChainProofTradingTokenProMethodologyMatch reviewLaunch readiness
Data sources
SEC FORM 45m ago
HOUSE PTR5m ago
SEC 13F5m ago
ROBINHOOD CHAIN4m ago
Public company

HALOHALOZYME THERAPEUTICS, INC.

CIK 0001159036

EDGAR filingsOpen in network
Disclosed transactions2
Buys / sells1 / 1
Max Insider Score27
Connections3with evidence

HALO · disclosed activity on price

Disclosed transactions

ScoreActorSecuritySideValueExecutedDisclosedLagSourceEvidence
27
Gilbert Ray Cisneros, Jr.DSelf
HALOHALOZYME THERAPEUTICS, INC.
Partial sale
SELL$1,001 – $15KSep 29, 2026Oct 12, 2026
traded Sep 29, 2026
+13dHOUSE PTR

Evidence

Verified connections

  • In industryevidence
    Pharmaceuticals, devices & health servicesSEC SIC 2836 · Biological Products, (No Diagnostic Substances) · Nov 4, 2026
  • ← Disclosed trade inevidence
    Gilbert Ray Cisneros, Jr.Sale disclosed 2026-10-12 · Oct 12, 2026
  • ← Lobbied forevidence
    FORBES-TATELDA Q2 2026 second quarter · Medicare/Medicaid, Health issues · Aug 26, 2026
24
Gilbert Ray Cisneros, Jr.DSelf
HALOHALOZYME THERAPEUTICS, INC.
Purchase
BUY
$1,001 – $15K
Mar 9, 2026
Apr 7, 2026
traded Mar 9, 2026
+29d
HOUSE PTR

Evidence

Lobbying

$150K reported · de-duplicated
2026 Q2 $80K via firms2026 Q1 $70K via firms
  • FORBES-TATE$70K2026 Q1 · posted Aug 26, 2026 · Health issues, Medicare/Medicaid
  • FORBES-TATE$80K2026 Q2 · posted Aug 26, 2026 · Medicare/Medicaid, Health issues

Connected PAC contributions

FEC · direct to members

No contributions from a PAC connected to this company.